Teleflex (TFX) Proxy filing summary

Executive summary

• Annual meeting scheduled for May 15, 2026, to elect seven directors, approve executive compensation, and ratify the external auditor.

• Strategic transformation underway, including acquisition of BIOTRONIK's Vascular Intervention business and divestiture of Acute Care, Interventional Urology, and OEM businesses, expected to close in the second half of 2026 with $1.8 billion net proceeds.

• Proceeds to fund a $1 billion share repurchase and $800 million in debt reduction, with a focus on core critical care and high-acuity hospital markets.

• CEO transition in January 2026, with an interim CEO appointed and a search for a permanent CEO ongoing.

Voting matters and shareholder proposals

• Shareholders will vote on the election of seven directors, an advisory say-on-pay vote for executive compensation, and ratification of PricewaterhouseCoopers LLP as independent auditor for 2026.

• Proxy access bylaw allows eligible shareholders to nominate directors; proposals for the 2027 meeting must be submitted by December 16, 2026.

Board of directors and corporate governance

• Board reduced to seven members post-meeting, with a focus on diversity, independence (86% independent), and relevant expertise.

• Independent Chair structure adopted in 2026; regular executive sessions held by non-management directors.

• Annual board and committee self-assessments; robust stockholder engagement program influencing governance changes, including board declassification and elimination of supermajority voting.

• Proxy access and special meeting rights enhanced in response to shareholder feedback.